Product complaint #: (b)(4).Attempts to obtain the information have been made and received.The device is not received to date.If the further details are received at a later date a supplemental medwatch will be sent.Was the doctor told not to use the sample, prineo: clr222/lot: mqk134 on the patient? yes.Were there any markings on the labeling to not use on patients? the label not for sale on the prineo.It was noted an antibiotic was prescribed, was there any other medical or surgical treatment provided to address the blister and /or wound dehiscence? profilactic antibiotic: cefuroxima 500mg every 12 hours.Please describe how was the adhesive was applied.The following information need to be discussed with the doctor: what prep was used prior to, during or after prineo use? the following information need to be discussed with the doctor: was a dressing placed over the incision? if so, what type of cover dressing used? the following information need to be discussed with the doctor: what tissue dehisced? the following information need to be discussed with the doctor: was there any deficiency of the 2 stratafix sutures? if yes, please describe.No.On what tissue layers were the 2 stratafix sutures used? fascia and dermis.What was the tissue condition, i.E., normal or thin, calcified, fragile, diseased? the following information need to be discussed with the doctor: can you describe the appearance of the stratafix suture upon noting the dehiscence? no issues with stratafix.Other relevant patient history/concomitant medications: no.If applicable, will product be returned, return date, tracking information: no.What is the patient¿s current status? she´s ok.What is physician¿s opinion as to the etiology of or contributing factors to this event? the doctor said that the patient history of smoking can be a factor.Note: events reported on mw# 2210968-2020-07689.
|
Product complaint #: (b)(4).Date sent to the fda: 10/28/2020.A manufacturing record evaluation was performed for the finished device batch and no non-conformances were identified.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon inc, or its employees that the report constitutes an admission that the product, ethicon inc or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|